Regis Healthcare Ltd.

As of June 30, 2026, Regis Healthcare Ltd. carries a market capitalization of 1.15B, placing it among publicly traded companies globally. Its enterprise value stands at 1.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Regis Healthcare Ltd.'s next confirmed earnings release is scheduled for February 23, 2027.

As of June 30, 2026, Regis Healthcare Ltd. has 302.26M shares outstanding.

As of June 30, 2026, Regis Healthcare Ltd. trades at a trailing price-to-earnings ratio of 34.09. The price-to-sales ratio is 1.41, and the price-to-book ratio stands at -156.66.

As of June 30, 2026, Regis Healthcare Ltd. trades at an EV/EBITDA multiple of 15.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.88 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.05B versus a market cap of 1.15B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Regis Healthcare Ltd. maintains a current ratio of 0.08, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -32.87, indicating conservative leverage, while an interest coverage ratio of 0.70 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) stands at 2.37, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -1,660.02, pointing to unprofitable operations over the period. The company generates approximately 62,932.14 in revenue per employee across its workforce of 13,000.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Regis Healthcare Ltd. recorded 16.98M in income tax expense. That works out to an effective tax rate of 33.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 50.71M, leaving 33.73M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on September 7, 2026.

Over the twelve months ended June 30, 2026, Regis Healthcare Ltd. generated 818.12M in revenue and converted that into 33.73M in net income, yielding earnings per share of 0.11. EBITDA reached 69.16M, while operating income came in at 35.08M.

As of June 30, 2026, Regis Healthcare Ltd. holds 105.26M in cash and equivalents against 2.42M in total debt, resulting in a net debt position of -105.26M. Total book value stands at -7.35M, with working capital of -1.44B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The operating margin of 4.29 and net profit margin of 4.12 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Regis Healthcare Ltd. paid dividends of 0.10 per share. The dividend payout ratio of 92.85 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.82, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Regis Healthcare Ltd. shareholders.

As of June 30, 2026, Regis Healthcare Ltd. has an Altman Z-Score of -0.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.